

# Index

*Note:* The following abbreviations are used: ADHD for attention deficit/hyperactivity disorder; ASD for autism spectrum disorder; CP for cerebral palsy; D/HH for deaf/hard of hearing; ID for intellectual disorder/disability; SB for spina bifida; TBI for traumatic brain injury; VI for visual impairment/visually impaired.

- absence and atonic seizures 359
- academic achievement/functioning
  - ADHD children 84, 91
  - and cerebral palsy 210
  - children with TBI 301, 322
  - epilepsy patients 362
  - learning disability
    - adults 149–150, 152, 156
    - children 127–128
  - pediatric leukemia 384
  - in spina bifida 172–173, 186–187, 188–189, 197–198
  - and visual impairment 286
- accommodations
  - for adults with ADHD 108
  - adults with LD 153–155, 157
  - children with SB 189
- acculturation, variable in assessment 58–59
- acquired brain injury and visual impairment 280–281
- acute lymphoblastic leukemia (ALL) *see* leukemia
- acute myelogenous leukemia (AML) *see* leukemia
- adaptive behavior/functioning
  - in autism, evaluation of 245
  - children treated for brain tumors 401
  - deficits in childhood TBI 301
  - intellectual disability 223, 224
  - in spina bifida 174, 188
- Addison's disease 417–418, 438
- adolescent development 183–185
  - and emerging adulthood 185
- adrenal gland disorders
  - congenital adrenal hyperplasia 418–419
  - hypercortisolism 417–418
  - hypocortisolism 417–418
- adrenoleukodystrophy (ALD) 431, 438
- cerebral ALD (C-ALD) 438
  - treatment and management 439–440
  - neuropsychological functioning 440
- adversity in early life 30
  - causing intellectual disability 228
  - “reserve” and resilience concepts 34
- age-related macular degeneration (AMD) 280
- age/timing
  - age of onset controversy, ADHD 98
  - brain development and ADHD 117
  - critical/sensitive period 26–27, 264, 415
  - of injury in TBI, effect on outcome 303
  - of leukemia diagnosis 381–382
  - timing of motor development in SB 170
  - variable in assessment 59–60
- aggression
  - following TBI 332–333
  - people with ID 231
- aging 41
  - attributes of normal and optimal 42–44
  - brain research
    - functional changes 46–50
    - structural changes 44–46
  - and chronic epilepsy 375–376
  - concepts of normal, healthy, and optimal 41–42
  - future directions 50–51
  - and hormones 419–421
  - intraindividual variability 49–50
- Alzheimer's disease
  - aging with epilepsy 375
  - role of estrogen 420
  - TBI as a risk factor for 332
  - and testosterone 420
  - vs. TBI, cognitive performance 350–351
- Americans with Disabilities Act (ADA) 145, 146, 292
- amygdala 9–10, 240
- androgen insensitivity 419
- androgen overexposure 418–419
- antiepileptic drugs (AEDs) 365
  - potential impact on functioning 474
  - vascular risk factors 375–376
- anxiety disorders 451
  - adults with TBI 333–334
  - children with epilepsy 364
- effect on performance 152, 450, 470
- and memory dysfunction 472
- people with ID 230
- apoptosis 12
- Applied Behavioral Analysis (ABA) 245
- arterial spin labeling (ASL) 74–75
- assessment and evaluation
  - of adults with TBI in childhood 317–320
  - and autism diagnosis 244–245
  - bipolar disorder in adults 460
  - brain tumors, children 402
  - children with cerebral palsy 210–212
  - clinical assumptions 35
  - clinical neuropsychological assumptions 35–36
  - deaf/HH individuals 267–270
  - endocrine disorders 421–422
  - learning disorders
    - in adults 150–154
    - in children 137–138
  - major depression 462, 464
  - neurodegenerative disease 428–431
  - pediatric cancer 386
  - spina bifida children and adults 176, 199–200
  - TBI in adulthood 335–336
  - TBI in childhood 303–307
  - visually impaired people 289–292
  - see also* multicultural issues in assessment
- assistive technology 190, 232, 245
- attention
  - in ADHD 91, 101–102
  - after brain tumor treatment 401
  - autism 241
  - cerebral palsy 208
  - D/HH individuals 264–265
  - epilepsy patients 364
  - pediatric leukemia and lymphoma 384
  - spina bifida 170–171, 186, 195
  - visually impaired people 284, 288
- attention deficit hyperactivity disorder (ADHD) 113–114, 122
  - current treatments and new directions 120–122

## Index

- attention deficit hyperactivity disorder (ADHD) (cont.)  
   directions for future research 122–123  
   and individuals with ID 231  
   neuropsychological heterogeneity 118–120  
   phenotypic variability 115–117  
   psychiatric comorbidities 117–118  
   theoretical conceptualizations 114–115  
 attention deficit hyperactivity disorder (ADHD) in adults 97  
   future research suggestions 109  
   key points 109–110  
   literature review 100  
     comorbidity issues 98–99  
     diagnostic issues 97–98  
     epidemiology 97  
     gender differences 99–100  
   neuroimaging studies 104–107  
   recent research 100, 104  
     additional executive functions 103  
     cognitive functioning 100–102  
     daily functioning 103–104  
     inattention 102  
     memory 102–103  
     neuropsychological measurement 104  
     response inhibition 102  
   treatment 107, 108–109  
     coping strategies/environmental modification 108  
     pharmacological 107  
     psychotherapy and psychoeducation 107–108  
 attention deficit hyperactivity disorder (ADHD) in children  
   comorbid with bipolar disorder 452  
   etiologic mechanisms 86, 93  
   future directions 92–93  
   interventions 88, 93  
     behavioral 88–89  
     clinical trials 89–90  
     cognitive remediation strategies 90–92  
     pharmacological 89  
   neuroimaging studies 86–88, 93  
   neuropsychology of 83–86, 93  
   phenomenology 83, 93  
 attenuated MPS I 436–437  
 auditory neuropathy/auditory dys-synchrony (AN/AD) 258  
 Autism Diagnostic Observation Schedule (ADOS) 244  
 autism spectrum disorders (ASDs) 239  
   behavioral link to VI children 286  
   brain–behavior relationships 241  
   cognitive manifestations 241  
     attention and memory 241–242  
     executive functioning 243  
     language 242  
     visual-spatial/perceptual skills 242–243  
   comorbidities 254  
   future research directions 246  
   and intellectual disability (ID) 251  
     cultural influence on screening and diagnosis 253  
     etiologies 251–252  
     ID stability and interventions 252–253  
     “optimal outcome” of ASD 252  
     prevalence rates 251  
     service availability, factors influencing 253  
     similarities with 253  
     transition periods 253–254  
   interventions 245–246  
   pathophysiology  
     abnormalities in social brain circuitry 240–241  
     head and brain growth 239–240  
   psychosocial and behavioral manifestation 243–244  
   role of assessment in diagnosing 244–245  
 Barkley, R. A. 107–108, 109  
 basal ganglia 8–9, 87  
 Bates, Elizabeth 29–30  
 Batten disease 434  
 behavior  
   adaptive behavior in ID 223  
   adjustment, children with SB 174  
   autism spectrum disorder 243–244  
   goal-directed, SB children 171–172  
   issues in measurement of 34–35  
   observation of, pediatric TBI 306  
   problem behavior in ID 230–231  
   visually impaired children 286  
   *see also* brain–behavior relationships  
 behavioral interventions  
   ADHD children 88–89, 108, 120–121  
   ASD children 245  
   TBI in adulthood 321  
 benzodiazepines, effects of long-term use 473–474  
 Biederman, J. 98, 99–100, 451–452  
 bipolar disorder 458–459  
   in adults  
     assessment issues 460  
     neuropsychological function 459–460  
     treatment 460  
   in children, and comorbid ADHD 452  
   in older adulthood 460–461  
 blindness *see* visual impairment  
 bone marrow transplant 381, 385, 435–436, 439–440, 441, 442  
 brain–behavior relationships  
   adult–child differences in 302–303  
   modeling 32–33  
     autism spectrum disorder 252  
 brain damage caused by TBI 330–331  
 brain development 12–13  
   aberrant brain growth in autism 239–240  
   in ADHD children 87–88, 117  
   cultural influences 23, 57  
   and early androgen overexposure 418–419  
   effect of brain tumor treatment 400  
   effect of early onset epilepsy 372–373  
   functional changes during aging  
     general functioning 46–48  
     intraindividual variability 49–50  
     specific cognitive function 48–49  
   impact of socioeconomic status 60–61  
   structural changes during aging 44–46  
 brain–experience interface, developmental models 30–31  
 “brain reserve” concept 34, 371, 374–375  
 brain structure(s) 5  
   age-related changes 44–46  
   in autism 240–241  
   brain cells 5  
   “brain reserve” concept 34  
   cranial nerves 6  
   mesencephalon 7  
   neurotransmitters 5–6  
   rhombencephalon 6–7  
   telencephalon 7  
 brain tumors 393  
   in adults 403  
     neuropsychological issues 403–404  
   in children 399–400  
     attention and working memory 401  
     characteristic deficits 400

- interventions 402–403
- long-term outcome of treatment 399–400
- psychosocial functioning 401
- role of neuropsychological assessment 402
- speed of information processing 401
- classification of 393–395
- epidemiology 393
- future research directions 404
- signs and symptoms of 396
- treatments 396–397
  - chemotherapy 398
  - radiation 397–398
  - surgery 397
- types of 395–396
- Broca, Paul 3
- Brodmann's areas 10–11
- cancer
  - and endocrine dysfunction 421
  - ototoxic drugs and hearing loss 263
  - see also* brain tumors; leukemia; lymphomas
- cataracts 278
- centenarians 44
- cerebellum 6–7, 87
- cerebral ALD (C-ALD) 438–440
- cerebral cortex 10–12, 86
- cerebral palsy (CP)
  - adulthood and aging issues 214–215
  - assessment issues 210–212
  - classification 205–206
  - definition of 205
  - epidemiology and etiology 206
  - impairments 207
  - neuropathology 206–207
  - neuropsychology 207
    - academic abilities 210
    - executive abilities 208
    - intelligence 207–208
    - language 210
    - learning and memory 208–209
    - psychomotor speed and attention 208
    - visual spatial and perceptual abilities 209–210
  - psychosocial development 212–213
    - family influences on social development 214
    - quality of life 214
  - research directions 215–216
- “cerebral reserve” concept 34, 371, 374–375
- cerebrovascular accident (CVA) and VI 280–281
- cerebrum *see* telencephalon
- chemotherapy
  - brain tumors 398
  - pediatric leukemia and lymphoma 380–381, 382
    - effects on cognition 382–386
- choice-making abilities, assessing in children with CP 211–212
- chromosome disorders 226, 421
- classroom behavior management 88–89
- cochlear implants 264, 267, 272
- Cogmed Working Memory Training Program 91
- cognitive development in children 283–284
- cognitive functioning
  - adults with ADHD 100–101
  - age-related decline in 46–49
  - autism spectrum disorders 241–243
  - deaf and HH people 264
  - in epilepsy patients 361–362
    - effect of early onset 371–372
    - effects of aging 375–376
    - following surgery 366
    - progression over the lifespan 373–375
  - estimation of pre-morbid 64
  - intraindividual variability 49–50
  - leukemia and lymphoma survivors 382–386
  - spina bifida 170–172, 186–187, 195–197
  - traumatic brain injury (TBI)
    - in adulthood 331–332
    - children 300
    - outcome in older people 347–351
    - survivors of childhood 318–319, 320–321
  - variance of across the lifespan 49
  - VI children and adults 283–284, 288
  - see also* intelligence
- cognitive remediation
  - for ADHD adults 108
  - ADHD children 90–92
- children with brain tumors 402–403
- for schizophrenia 457
- TBI in adults 337
- “cognitive reserve” 34, 371, 374–375
- coma, TBI patients 331
  - measures of 302, 329, 335
- communication development
  - blind and VI children 284–285
  - hearing impaired children 265
  - see also* language development
- comorbidity issues 450–451
  - ADHD in adults and children 98–99, 117–118
  - ADHD and disruptive behavior disorders 451–452
  - ADHD and mood disorders 452
  - in epilepsy 364
  - learning disorders 148
  - see also* substance use disorders
- conductive hearing loss 258
- congenital adrenal hyperplasia 418–419
- congenital hearing loss 262
- congenital rubella syndrome (CRS) 262
- conservation, blind children 283–284
- continuous spike-wave discharges during sleep 361
- corpus callosum 87, 372–373
- cortical electrical stimulation, epilepsy surgery 366
- cortical vision impairment (CVI) 280, 282
- corticosteroids, neurotoxic effects of 385
- cranial nerves 6
- cranial radiation therapy (CRT) 380
- crime and learning disorder 150
- critical/sensitive period 26–27, 264, 415
- crystallized intelligence 47–48, 58
- culture
  - acculturation 58–59
  - definitions of 56
  - developmental models 30–31
  - influence on screening and diagnosis 253
  - influencing assessment 57
- Cushing's syndrome 417–418
- daily functioning
  - adults with ADHD 103–104
  - individuals with ID 232
  - people with LD 156, 223–224
- deafness *see* hearing loss
- dementia
  - and chronic epilepsy 375–376
  - see also* neurodegenerative disorders
- Dennis, Maureen 29, 170, 171, 371
- depression
  - adults with TBI 333, 351
  - effect on neuropsychological assessments 450
  - effects on cognition 473
  - youth with SB 174
  - see also* major depression

## Index

- developmental models 17–18, 37  
 adolescence 183–185  
 adults and geriatrics 41  
   changes associated with aging 44–50  
   normal neurobiological aging 41–44  
 in clinical practice 19–21  
 concepts of 18–19  
 emerging adulthood 185  
 examples of  
   brain–behavior relationships 32–33  
   brain–experience interface 30–31  
   evolutionary models 27–29  
   modeling by domain 32  
   modeling by lesion 29–30  
   modeling by time 31–32  
   modeling from typical to atypical and back 31  
   models by disorder 29  
 heterogeneity of outcomes 33–34  
 implications of 35  
   clinical assumptions 35–36  
   for intervention 36–37  
 knowledge base of models 22  
   how question, addressing 24–27  
   when question, addressing 22–24  
 methodological issues 34–35  
 written language 136
- diabetes 414  
   pregestational and gestational diabetes 414–415  
   Type 1 diabetes 415–416  
   Type 2 diabetes 416–417
- diabetic retinopathy (DRP) 280
- diagnosis  
   ADHD 97–98, 449–450  
   autism 244–245, 251–252  
   definition and classification of CP 205–206  
   intellectual disability (ID) 221–222, 253
- learning disorders 143  
   diagnostic models 143–144  
   diagnostic terms and criteria 144–145  
   differential diagnosis 151–153  
   legal definitions 145–146  
   role of IQ 165  
   reading disability 165–166
- diffusion tensor imaging (DTI) 13, 71, 106, 339
- discrepancy model of learning disability 128, 143
- disinhibition syndromes, TBI 332–333
- Down syndrome (DS) 31, 226
- Dravet's syndrome 360
- dyslexia, brain abnormalities 149
- ear infections 149, 258, 263
- early intervention  
   for children with ADHD 121–122  
   for children with VI 292  
   for D/HH children 270  
   services of children with ID 233  
   services for children with SB 177
- electrical status epilepticus during sleep 361
- emotion  
   laterality of brain function in 11–12  
   role of amygdala 9
- emotional development *see* socio-emotional development
- employment  
   adults with LD 156  
   adults with SB 188  
   benefits for TBI survivors 319  
   people with CP 215  
   *see also* vocational interventions
- endocrine disorders 409  
   androgen insensitivity 419  
   assessment implications 421–422  
   conditions associated with 421
- diabetes 414  
   pregestational and gestational diabetes 414–415  
   Type 1 diabetes 415–416  
   Type 2 diabetes 416–417
- disorders of the adrenal gland  
   congenital adrenal hyperplasia 418–419  
   hypercortisolism 417–418  
   hypocortisolism 417–418
- endocrine system overview 409
- hormones and aging  
   estrogens and progesterone 420  
   growth hormone 420–421  
   melatonin 421  
   testosterone 419–420
- parathyroid disease  
   hyperparathyroidism 413–414  
   hypoparathyroidism 412–413
- thyroid disease  
   Hashimoto's encephalopathy 412–413  
   hyperthyroidism 411–412  
   hypothyroidism 409–411
- environmental influences  
   children with TBI 303  
   leading to ID 228–229  
   nature–nurture debate 18  
   spina bifida (SB) 175–176, 199
- enzyme replacement therapy (ERT) 435, 443
- epilepsy 359, 366–367  
   classification of seizures 359–361  
   comorbidities 364  
   epidemiology 361  
   future directions 367  
   lifespan perspective 371, 376  
     aging and cognitive status 375–376  
     cognitive progression 373–375  
     cognitive reserve 371  
     early onset and brain status 372–373  
     early onset and cognitive status 371–372  
   long-term outcomes 366  
   neuropsychological findings 361–364  
   social functioning 364–365  
   treatment  
     antiepileptic drugs (AEDs) 365  
     surgery 73–74, 365–366
- epileptic encephalopathies 360–361
- equipotentiality 3–4
- estrogens, age-related effects of 420
- ethical issues in assessment  
   multicultural testing 61–63  
   visually impaired individuals 290–291
- ethnicity, definition 57
- evidence-based practice 19–20  
   and model-building 20–21
- evolutionary models of development 24, 27–29
- executive functioning (EF)  
   adults with ADHD 102–103  
   adults with VI 288  
   in autism 243  
   children with ADHD 119–120  
     enhancement of 92  
   children with epilepsy 364  
   children with VI 284  
   D/HH individuals 264–265  
   evolutionary models 27–28  
   “hot” and “cool” processes 104  
   pediatric leukemia 384–385  
   in spina bifida 186, 189, 196
- expertise of clinicians 20, 307
- eye conditions  
   cortical vision impairment (CVI) 280  
   refractive errors 279–280  
   structural abnormalities 278–279
- Fabry disease 433
- face processing 240–241, 242–243

- families  
   of adolescents with SB 187  
   and assessment of VI 290  
   impact of childhood TBI 302  
   influence on social development of  
     CP children 214  
   of SB children, support for 177
- family interventions  
   children with SB 177  
   for deaf and HH children 270  
   for TBI children 308
- Faraone, S. V. 98
- fluid intelligence 47–48, 58
- focal idiopathic epilepsies of  
   childhood 360
- Fragile-X syndrome 226
- frontal lobes  
   activation in adults with ADHD 106  
   executive function link 27–28
- functional MRI (fMRI)  
   adults with ADHD 106–107  
   advanced techniques 72–74  
   children with ADHD 87  
   evaluating medication effects 106  
   limitations and considerations  
     76–78  
   TBI studies 339
- functional near-infrared spectroscopy  
   (fNIRS) 75
- Gaucher disease 433
- gender differences 60  
   in adult ADHD 99–100  
   in brain volume loss with age 45  
   in learning disabilities 148  
   pediatric cancer 381
- generalized idiopathic epilepsies 360
- genetics  
   epigenetic processes 25  
   etiology of ASDs and ID 251–252  
   gene expression profiling,  
     leukemia 382  
   genetic disorders causing ID  
     225–227  
   hereditary deafness 261–262  
   heritability of ADHD 86, 93  
   modeling behavior with 25–26  
   pediatric leukemia link to ADHD  
     385–386  
   reading disorders 147  
   spina bifida 169
- Glasgow Coma Scale (GCS) 302, 329
- glaucoma 278
- globoid cell leukodystrophy (GLD) 442  
   neuropsychological functioning 442  
   treatment 442
- GM1 gangliosidosis 434
- GM2 gangliosidosis 434
- goal-directed behavior, children with  
   SB 171–172
- Graves' disease 411–412
- gray matter, age-related decline in  
   45, 46
- growth hormone 420–421
- handwriting skills 136–137
- Hashimoto's encephalopathy 412–413
- head injury  
   in childhood, ID resulting from  
     228–229  
   *see also* traumatic brain injury (TBI)
- hearing loss 257  
   assessment 267–270  
   characteristics 257–258  
   epidemiology 259  
   etiology 259–261  
     hereditary deafness 261–262  
     non-hereditary causes 262–263  
   future research directions 271–272  
   hearing system anatomy 259  
   identification and management  
     258–259  
   intervention 270–271  
   neuropsychological correlates  
     263–264  
     attention and executive  
       functioning 264–265  
     general cognitive functioning 264  
     language 265  
     memory 266  
     motor development 266  
     social-emotional development  
       266–267  
     visuospatial cognition 265–266
- hematopoietic stem cell transplantation  
   (HSCT) 381, 385, 439–440, 441,  
   442
- hereditary deafness 261–262
- heterogeneity  
   in ADHD 113  
   neuropsychological 118–120  
   of psychiatric comorbidities  
     117–118  
   in ASD phenotype 241, 251–252  
   of developmental outcomes 33–34  
   “heterotypic continuity” 451
- hindbrain structures 6–7
- hippocampus 10  
   age-related degradation of 44–45  
   damage from cranial radiation 398
- Hodgkin lymphoma (HL)  
   *see* lymphomas
- hormone replacement therapy  
   (HRT) 420
- hormones and aging  
   estrogens and progesterone 420  
   growth hormone 420–421  
   melatonin 421  
   testosterone 419–420
- Hunter syndrome 437
- Hurler Scheie syndrome 436–437
- Hurler syndrome 432–436
- hydrocephalus secondary to spina  
   bifida 195–200
- hypercortisolism 417–418
- hyperparathyroidism 413–414
- hyperthyroidism 411–412
- hypocortisolism 417–418
- hypoparathyroidism 412–413
- hypothalamus 8, 409
- hypothyroidism 409–411
- hypoxia, causing hearing loss 262–263
- imaging techniques *see* neuroimaging
- inattention  
   and absence seizures 364  
   in ADHD adults 102  
   *see also* attention
- inborn errors of metabolism (IEM)  
   427–428
- neuropsychological evaluation 428  
   age equivalent scores/raw scores  
     for monitoring 429–430  
   clinical recommendations 431  
   correlations with neuroimaging  
     and biological markers  
     430–431  
   importance of child's physical  
     condition 430  
   predictors of outcome 430  
   repeated testing and practice  
     effects 428–429  
   test selection and consistency 429  
   testing tips 430  
   treatment outcome  
     monitoring 431  
   phenylketonuria (PKU) 227  
   *see also* lysosomal and peroxisomal  
     disease
- independence  
   individuals with ID 233  
   people with SB 188, 199
- Individuals with Disabilities Education  
   Act (IDEA) 128
- Individuals with Disabilities Education  
   Improvement Act of 2004  
   (IDEIA) 143–144, 145–146,  
   165, 292
- infections, causing hearing loss  
   262, 263
- inflammation and cognitive aging 376



## Index

- information gathering 470–472  
 information processing speed *see*  
   processing speed  
 initiation impairments, TBI 333  
 injury severity and outcome of TBI  
   302–303  
 intellectual disability (ID) 221  
   and autism spectrum disorders  
   (ASDs) 251–254  
   controversial areas 222  
   adaptive behavior 223  
   intelligence 222–223  
   level of functioning 223–224  
   definitions/diagnostic criteria 221–222  
   developmental junctures 232–233  
   etiologies 224–225  
     childhood causes 228–229  
     intrauterine exposures 227  
     perinatal complications 227–228  
     preconceptual stage 225–227  
   interventions 229–229  
   importance of early 252–253  
   occupational and physical therapy  
   needs 232  
   use of assistive technology 232  
   psychopathology and problem  
   behavior  
     ADHD 231  
     anxiety and psychotic  
     disorders 230  
     language difficulties 231–232  
     mood disorders 229–230  
     stereotyped and self-injurious  
     behavior 230–231  
   role of neuropsychologists 234  
 intelligence  
   assessment of childhood TBI 300  
   assessment of, VI people 291  
   cerebral palsy (CP) 207–208  
   crystallized vs. fluid 47–48, 58  
   decline following chemotherapy  
   382–384  
   ID diagnosis 222–223  
   reading disability diagnosis 165–166  
 interleukin-6, risk factor for  
   age-associated decline 43–44  
 interventions 36–37  
   ADHD 114, 120–122  
   in adults 107–108  
   in children 88–90  
   ASDs 245–246, 252–253  
   hearing loss 270–271  
   intellectual disability (ID) 229–229,  
   252–253  
   learning disorders (LDs) 154–157  
   mathematics disorder 135  
   reading disorder 137–132  
   research synthesis 166–167  
   written expression 137  
 spina bifida (SB) 177, 200  
 traumatic brain injury (TBI)  
   in adulthood 336–338  
   in childhood 308–309  
   post-TBI impairments 320–323  
   visual impairment 292  
   *see also* treatment  
 intracarotid amobarbital test (IAT or  
   Wada) 73–74, 365  
 intraindividual variability in older  
   adults 49–50  
 intrauterine exposures leading  
   to ID 227  
 Jackson, John Hughlings 3  
 Klinefelter's Syndrome 421  
 Krabbe disease 442  
 Landau-Kleffner syndrome (LKS) 361  
 language  
   adolescents and adults with SB 186, 196  
   in autism spectrum disorder  
   (ASD) 242  
   cortical language mapping,  
   epilepsy 366  
   effects of childhood TBI 300–301  
   laterality of brain function 11  
   processing in epilepsy 362  
   sign language 259, 265  
   use of fMRI prior to epilepsy surgery  
   73–74  
   written language disorder 135–137  
 language development  
   blind and VI children 284–286,  
   287–288  
   brain-behavior relationships 33  
   brain structures involved in 29–30  
   children with SB 172, 176, 196  
   deaf/hearing-impaired children  
   258–259, 265  
   delay in individuals with ID 231–232  
   effect of socioeconomic status 60  
   sociocultural experiences 31  
 Lashley, Karl 3  
 lateralization of brain function 11–12  
   language and epilepsy 73–74, 365  
 lead exposure, effects of 228  
 learning disorders (LDs) 163  
   in adults 143, 164  
   assessment 150–151; areas to  
   assess 153; background history  
   151; differential diagnosis  
   151–153; specific evaluation  
   needs 153–154  
   associated features 148–150  
   characteristics and features  
   146–147; comorbidity 148;  
   course and prognosis 147;  
   demographics 148; etiology  
   147; prevalence 147–148  
   diagnosis 143–145; legal  
   definitions 145–146  
   future directions 157–158  
   resources for 157  
   treatment 154; effectiveness of  
   166–167; primary treatment  
   settings 156; self-advocacy  
   156–157; types of treatment and  
   treatment issues 154–155  
 in children and adolescents 163–164  
   assessment/evaluation 127  
   classification and diagnosis 127  
   disorder of written expression  
   135–137  
   future directions 138–139  
   mathematics disorder 132–135  
   models for identifying and placing  
   128  
   reading disorder 129–132  
   role of neuropsychological  
   assessment 137–138  
   socio-emotional functioning 138  
   definition/identification of 164–165  
   research emphasis on RD 164  
   role of IQ in diagnosis of 165  
   alternatives to discrepancy model  
   165–166  
 left-handedness 11  
 legal definitions of learning disability  
   145–146  
 Lennox-Gastaut syndrome 361  
 lesions, developmental models based  
   on 29–30  
 leukemia 379  
   evaluation and management  
   386–387  
   future directions 387–388  
   late effects 388  
   mediators and moderators  
   381–382  
   neurocognitive outcomes  
   382–386  
   pathophysiology 379  
   treatment 380–381  
 leukodystrophies 438  
   adrenoleukodystrophy (ALD) 438  
   neuropsychological  
   functioning 440  
   cerebral ALD (C-ALD) 438  
   treatment and management  
   439–440

## Index

- globoid cell leukodystrophy (GLD) 442  
 neuropsychological functioning 442  
 treatment 442  
 metachromatic leukodystrophy (MLD) 440–441  
 neuropsychological functioning 441–442  
 treatment 441  
 “life underachievement,” adults with LD 149–150  
 lifestyle factors and cognitive decline 42–43, 376  
 limbic system 9–10  
 literacy  
 effect on brain development 30–31  
 effect on earnings 150  
 protective factor in memory decline 59–60  
 localization of brain function 3–4, 11  
 reading disabilities 131–132  
 use of fMRI prior to surgery 72–74  
 localization-related (focal) seizures 359–360  
 Luria, Alexandr Romanovich 4  
 lymphomas 379, 388  
 evaluation and management 386–387  
 future directions 387–388  
 mediators and moderators 381–382  
 neurocognitive outcomes 382–386  
 pathophysiology 379–380  
 treatment 380–381  
 lysosomal and peroxisomal disease 431–432  
 future directions 442–443  
 mucopolysaccharidoses 432  
 mucopolysaccharidosis type I (MPS I) 432  
 attenuated MPS I 436–437  
 Hurler syndrome 432–436  
 mucopolysaccharidosis type II (MPS II) 437  
 mucopolysaccharidosis type III 437  
 mucopolysaccharidosis type VI 437–438  
 other lysosomal diseases 433–434  
 MacArthur Foundation studies of aging 42–44  
 magnetic resonance imaging (MRI)  
 advanced techniques 70–75  
*see also* functional MRI (fMRI); structural MRI  
 magnetic resonance spectroscopy (MRS) 71–72  
 major depression 461–461  
 in early and middle adulthood  
 assessment issues 462  
 neuropsychological function 461–462  
 treatment 462–463  
 in older adulthood 463  
 assessment issues 464  
 neuropsychological function 463–464  
 patients with TBI 351  
 treatment 464  
 malnutrition, source of ID 228  
 maternal diabetes 414–415  
 mathematics ability  
 in children with CP 210  
 disabilities in SB children 173  
 mathematics disorder 132–133, 144  
 epidemiology of 133  
 interventions for 135  
 neuroanatomical features 134–135  
 subtypes of 133–134  
 medical procedures, preparing children for 177  
 medication  
 using PET to study effects of 106  
*see also* pharmacological interventions  
 melatonin 421  
 memory  
 ADHD adults 102–103  
 and anxiety disorders 472  
 in autism spectrum disorder (ASD) 242  
 and brain tumor treatment 401  
 cerebral palsy children 208–209  
 in deaf/HH individuals 266  
 and epilepsy 363–364  
 and learning disability 149  
 spina bifida 186, 197  
 in visually impaired adults 288  
 mental illness *see* psychopathological conditions  
 mercury exposure, effect on IQ 228  
 mesencephalon 7  
 metabolic diseases *see* inborn errors of metabolism (IEM)  
 metachromatic leukodystrophy (MLD) 440  
 neuropsychological functioning 441–442  
 phenotypic variability 440–441  
 treatment 441  
 methotrexate (MTX) 380–381  
 neurocognitive problems 384  
 and white matter changes 382–383  
 midbrain structures 7  
 mood disorders  
 individuals with ID 229–230  
*see also* bipolar disorder; depression  
 motor development/functioning  
 blind and visually impaired children 282–283  
 deaf children 266  
 spina bifida (SB) 170, 171, 187, 196  
 MTA study, childhood mental health 89–90  
 mucopolysaccharidoses 432  
 mucopolysaccharidosis type I (MPS I) 432  
 attenuated MPS I 436–437  
 Hurler syndrome 432–436  
 mucopolysaccharidosis  
 Type II 437  
 mucopolysaccharidosis Type III 437  
 mucopolysaccharidosis Type VI 437–438  
 multicultural issues in assessment 55, 65–66  
 acculturation 58–59  
 age effects 59–60  
 definitions of cultural variables 56–57  
 ethical considerations 61–63  
 gender effects 60  
 impact of culture, ethnicity, and race 57–58  
 neuropsychological measures 64–65  
 pre-assessment procedures 63–64  
 pre-morbid estimation of function 64  
 socioeconomic status 60–61  
 theoretical considerations 55–56  
 myelination 13, 27  
 myelomeningocele *see* spina bifida (SB)  
 myoclonic atstatic epilepsy 361  
 neural tube defects 12  
*see also* spina bifida (SB)  
 neuroanatomy  
 brain development 12–13  
 brain structure 5–12  
 development of functional neural systems 3–5  
 neurodegenerative disorders 427–428  
 Alzheimer’s disease and TBI 332, 350–351  
 leukodystrophies 438–442  
 lysosomal and peroxisomal disease 431–438  
 neuropsychological evaluation 428–431

## Index

- Neurodevelopmental Systems Model 304–305  
 neuropsychological evaluation 305–307  
 neuropsychological management 307–309  
 neurogenesis 46  
 neuroimaging 17–18, 69  
   adults with ADHD 104, 106–107  
   diffusion tensor imaging (DTI) 106  
   medication effects 106  
   MRI findings 104–106  
   adults with reading disability 149  
   advanced techniques 70–76  
   bipolar disorder 459–459, 461  
   children with ADHD 86–88  
   in children with epilepsy 373  
   conventional methodologies 69–70  
   deaf individuals 263–264, 265  
   integrative and future directions 79  
   limitations and considerations 76–78  
   neurodegenerative diseases 430–431  
 neuronal plasticity 26  
   in the aging brain 46  
   in blind people 288  
   erroneous ideas 323  
   and mental retardation 253  
   and outcomes after childhood TBI 317–318  
   and reading acquisition 30–31  
   sensitive period for 26–27  
   synaptic plasticity 13  
 neurons 5  
 neurotransmitters 5–6  
   and ADHD 86  
 Niemann Pick diseases (A, B and C) 433  
 noise-induced hearing loss 263  
 non-Hodgkin lymphoma (NHL)  
   lymphomas  
 nonverbal deficits, children with  
   epilepsy 362–364  
 object permanence, blind children 283  
 older adults  
   bipolar disorder in 460–461  
   with chronic epilepsy 375–376  
   hearing loss affecting 263  
   major depression in 463–464  
   schizophrenia in 457–458  
   social isolation of deaf people 266  
   traumatic brain injury in 345–352  
   visually impaired  
     assessment of 292  
     cognitive function 288  
   *see also* aging  
   optic nerve hypoplasia (ONH) 278–279, 286  
   otitis media and conductive hearing loss 263  
   ototoxic drugs and hearing loss 263  
   outcome, modeling by 32  
 parathyroid disease  
   hyperparathyroidism 413–414  
   hypoparathyroidism 412–413  
 parenting  
   behavioral parent training (BPT) 88  
   of children with CP 214  
   of children with SB 175–176, 187  
   interactions in VI 287–288  
   interventions, children with SB 177  
 Pendred syndrome 261–262  
 perfusion MRI techniques 74–75  
 perinatal complications  
   leading to hearing loss 262–263  
   leading to IDs 227–228  
 peroxisomal disease *see*  
   adrenoleukodystrophy (ALD)  
 personality disorders  
   comorbid with ADHD 99, 117–118  
   comorbid with BP 460  
   and learning disability 152  
 perspective-taking, blind children 285  
 pervasive developmental disorders 152, 239  
 pharmacological interventions  
   ADHD 89–90, 107, 231  
   antiepileptic drugs for epilepsy 365  
   bipolar disorders 460  
   children with brain tumors 402  
   for depression 463  
   following TBI 308, 337–338  
   pharmacotherapy for ASD 245  
   psychopathological conditions 473–474  
   for schizophrenia 458  
 phenylketonuria (PKU) 227  
 phonological awareness 130, 131  
   children with cerebral palsy 210  
   interventions 137–132, 137  
   necessary for spelling 136  
   neuroanatomical features of 131  
 phrenology 3  
 plasticity *see* neuronal plasticity  
 Pompe disease 434  
 positron emission tomography (PET) 70  
   advanced techniques 75–76  
   limitations 77  
   studying effects of medication 106  
 post-traumatic amnesia (PTA) 302, 329, 331, 335–336  
 post-traumatic stress disorder (PTSD) 333–334  
 practice effects 318, 374, 428–429  
 pregestational and gestational diabetes 414–415  
 presbycusis, age-associated hearing loss 263  
 Preschool ADHD Treatment Study (PATs) 90  
 preterm infants  
   developmental models 30  
   and intellectual disability 227–228  
   and reduced visual perception 209–210  
 problem solving 128, 165–166, 171–172  
 processing speed  
   children with brain tumors 401  
   children with epilepsy 363  
   and cognitive decline with age 48–49  
   in pediatric leukemia 383  
 progesterone, age-related changes 420  
 psychometric tests  
   cross-cultural bias, avoiding 64–65  
   measure of behavior outcome 34  
   *see also* assessment and evaluation  
 psychopathological conditions 469–470  
   in adults 455, 464–465  
     bipolar disorder 458–461  
     major depression 461–464  
     schizophrenia 455–458  
   in children and adolescents 449–453  
   classification issues 472–473  
   future research 474  
   information gathering 470–472  
   in people with ID 230  
   treatment effects 473–474  
 psychosocial functioning  
   adolescents and adults with  
     SB 173–174, 187–188, 190, 198  
   autism spectrum disorders 243–244  
   children with CP 212–214  
   children with learning disorders 138  
   children treated for brain tumors 401  
   program for ADHD children 89  
   TBI in adulthood 334–335  
   TBI in childhood 301  
   visually impaired adults 289  
 psychotherapy  
   ADHD adults 107–108  
   LD adults 155  
   spina bifida (SB) 200



- quality of life (QoL)  
 children with CP 212–213  
 cochlear implant users 267  
 D/HH people 266–267, 270, 272  
 patients with brain tumors 403–404  
 people with cerebral palsy 214  
 visually impaired adults 289
- race  
 APA definition 57  
 impact on assessment 57–58, 62  
 and visual impairment 278
- radiation therapy  
 for brain tumors 397–398  
 and decline in IQ 400  
 for leukemia and lymphoma 380
- rapport, establishing during  
 assessment 290
- reading acquisition, and brain plasticity  
 30–31
- reading comprehension 131, 132
- reading disorder (RD) 129, 144  
 differential diagnosis 130  
 epidemiology 129–130  
 genetic research 147  
 interventions for 137–132  
 neuroanatomical features 131–132  
 prevalence 129  
 specific deficits with 130–131
- reading fluency 130–131
- Rehabilitation Act (1973) 146, 292
- repetitive behavior, ASD and ID  
 individuals 230–231, 239, 243
- resilience 34, 61
- response inhibition in ADHD 85,  
 87, 102
- responsive parenting style 175–176, 177
- retinopathy of prematurity (ROP) 278
- rhombencephalon 6–7
- RTI problem-solving model,  
 identification of LD 128,  
 165–166
- Rutter, M. 451
- Sandhoff disease 434
- SARAH program, TBI 322–323
- schizophrenia 455–456  
 in early- and middle-adulthood  
 assessment issues 456–457  
 neuropsychological function 456  
 treatment 457  
 in older adults  
 assessment issues 458  
 neuropsychological function 457  
 treatment 458
- screening for metabolic diseases  
 442–443
- segmental autosomal disorders 226
- seizures *see* epilepsy
- self-advocacy, adults with learning  
 disability 156–157
- self-awareness deficits, TBI 333
- self-injurious behavior 230–231
- sensorineural hearing loss (SNHL) 258
- sensory loss with age, effect on  
 cognitive functioning 48
- sexuality, people with SBM 188
- sign language 259, 265  
 socio-emotional development of  
 users 267
- single photon emission computed  
 tomography (SPECT) 70
- sinistrality 11, 148
- social functioning  
 adults with LD 155  
 in ASD children, interventions 245  
 cerebral palsy (CP) 213–214, 215  
 children with brain tumors 401  
 developmental models 32  
 epilepsy 364–365  
 evolutionary models 28–29  
 spina bifida (SB) 174, 187–188, 198  
 visually impaired adults and children  
 285, 287, 289  
 young deaf/HH people 270–271
- socio-emotional development  
 cerebral palsy (CP) 212–214  
 children with ID 138  
 deaf/HH individuals 266–267  
 emotional adjustment, SB 187  
 visually impaired people  
 286–288, 289
- socioeconomic status (SES)  
 and availability of services 253  
 impact on SB children 175  
 and learning disorder 148  
 moderating factor in assessment 60–61
- sound localization 259
- “specific learning disability” (SLD),  
 legal definition 145–146
- spelling problems 136, 137
- spina bifida (SB) 12  
 adolescents and adults 183, 191  
 assessment, purpose of 191  
 clinical implications 188–190  
 cognitive functioning 186–187  
 medical challenges 185  
 models of development 183–185  
 psychosocial adaptation 187–188  
 role of the neuropsychologist  
 190–191  
 children 169  
 academic achievement 172–173  
 clinical implications 176–177
- cognitive functioning 170–172  
 developmental models 29,  
 169–170  
 environmental influences  
 175–176  
 future research 177–178  
 psychosocial adaptation and  
 behavior adjustment 173–174  
 developmental synthesis 195  
 academic achievement 197–198  
 cognitive functioning 195–197  
 family functioning 199  
 future directions 200  
 psychosocial adaptation 198  
 role of neuropsychology 199–200  
 social adjustment 198
- Spirit Catches You and You Fall Down,*  
*The* (Fadiman) 55
- stereotyped behavior, people with ID  
 230–231
- “stereotyped threat,” ethnic  
 minorities 58
- strabismus 278
- stressors of poverty, effect on cognitive  
 development 61
- stroke survivors and VI 281
- structural MRI 69–70  
 children with ADHD 86–87
- substance use disorders  
 LD people 150, 151  
 schizophrenia patients 456–457  
 study of bipolar disorder  
 patients 471
- Summer Treatment Program (STP),  
 ADHD children 89
- support groups for adults with LD 155
- surgery  
 for brain tumors 397  
 epilepsy 73–74, 365–366
- synaptogenesis and synaptic plasticity  
 12–13
- Tay Sachs disease 434
- telencephalon 7  
 basal ganglia 8–9  
 cerebral cortex 10–12  
 hypothalamus 8  
 limbic system 9–10  
 thalamus 7–8
- teratogens 227
- testosterone  
 age-related effects of 419–420  
 androgen insensitivity 419  
 congenital adrenal hyperplasia  
 418–419
- thalamus 7–8
- theory of mind 285

## Index

- thyroid disease  
   Hashimoto's encephalopathy 412–413  
   hyperthyroidism 411–412  
   hypothyroidism 409–411  
 time, modeling by 31–32  
 tonic-clonic seizures 359  
 Tools of the Mind program, ADHD children 92  
 transitions  
   from child to adult care 189–190, 199  
   periods in lives of children with ID and ASD 253–254  
   to independence and adulthood 188, 191, 233  
 traumatic brain injury (TBI) across the lifespan 357–358  
 traumatic brain injury (TBI) in adulthood 329  
   assessment 335–336  
   brain, effect on 330–331  
   classification of injury severity 329  
   cognitive impairment 331–332  
   future directions 338–339  
   interventions 336–338  
   neurobehavioral effects 332  
   disinhibition syndromes 332–333  
   impairments of self awareness 333  
   initiation impairment 333  
   neuropsychiatric disorders 333–334  
   psychosocial effects 334–335  
 traumatic brain injury (TBI) in childhood 299  
   adult outcomes of 315  
     assessment 317–318, 320;  
       cognitive 318–319; emotional, social and behavioral 319–320;  
       vocational 319  
     functional manifestations 316–317  
     future directions 323–324  
     interventions 320; cognitive 320–321; educational and vocational 321–322; emotional, social and behavioral 321;  
     novel, innovative approaches 322–323  
   epidemiology 299, 315  
   future research directions 309–310  
   neuropsychological assessment 303–305; neuropsychological evaluation 305; historical data 305–306; observational data 306; psychological test data 306–307  
   neuropsychological management 307; educational support 308–309; pharmacological intervention 308; psychosocial intervention 308; rehabilitation 307–308  
   outcomes 300–300  
     cognitive 300–301  
     educational 301  
     factors influencing 302–303  
     familial 302  
     functional 301  
     psychosocial 301  
     pathophysiology 299–300, 315–316  
     prevention 309  
   traumatic brain injury (TBI) in older adults 345  
     affective functioning 351, 352  
     cognitive outcome 347  
       according to injury severity 349–350  
     cognitive recovery 349, 352  
     early cognitive manifestations 348–349  
     vs. Alzheimer's disease 350–351, 352  
   risk factors affecting outcome 351–352  
     age 345  
     pathophysiological issues 347  
     physical and cognitive status 347  
     severity of injury 345–347  
   treatment  
     brain tumors 396–398  
       in adults 403  
       in children 402–403  
     cerebral ALD (C-ALD) 439–440  
     epilepsy 365–366  
     Hurler syndrome 435  
     Krabbé disease 442  
     metachromatic leukodystrophy (MLD) 441  
     neurodegenerative disorders 431  
     pediatric cancer 380–382, 386–387  
     psychopathology 473–474  
       bipolar disorder 460  
       major depression 462–463, 464  
       schizophrenia 457, 458  
     *see also* interventions  
   tumors *see* brain tumors  
 Turner syndrome 133, 421  
 Type 1 diabetes 415–416  
 Type 2 diabetes 416–417  
 typical development, modeling from 31  
 Usher's syndrome 261  
 vascular risk factors in epilepsy 375–376  
 Victoria Longitudinal Study, aging 43  
 virtual reality technology, TBI rehabilitation 322, 339  
 visual impairment 277  
   assessment 289–291  
     in specific populations 291–292  
   children with spina bifida 171  
   cognitive and psychosocial sequelae 281  
     in adulthood 288–289  
     in children 281–282; academic functioning 286; behavioral characteristics 286; cognitive development 283–284; executive function 284; language and communication 284–286; motor development 282–283; social and emotional development 286–288  
   future directions 293  
   pathophysiology in children and adults  
     acquired injury in adults 280–281  
     age-related macular degeneration (AMD) 280  
     cortical vision impairment (CVI) 280  
     diabetic retinopathy (DRP) 280  
     refractive errors 279–280  
     structural abnormalities 278–279  
   prevalence 277–278, 280  
   prevention and intervention 292  
 visual-spatial processing  
   in autism spectrum disorders 242–243  
   deaf/HH people 265–266  
   epilepsy patients 362–363  
   in spina bifida (SB) 171, 186, 196–197  
 vocabulary acquisition 31  
   effect of environmental information 33  
   visually impaired children 285, 286–287  
 vocational interventions  
   training for adolescents with SB 189  
   traumatic brain injury (TBI) 321–322  
 voxel-based morphometry (VBM) 70–71

Waardenburg's syndrome 261	and age of epilepsy onset 372–373	enhancing in ADHD children 91–92
WADA test prior to epilepsy surgery 73–74, 365	age-related decline in 45–46	and mathematic ability 135
web-based technology for TBI interventions 323	damage in cerebral palsy 206	people with spina bifida 173, 197
web resources for clinicians 324, 443–444	damage from radiation 398, 400	written expression disorder 135–136
West Syndrome 361	demyelination in ALD 438, 440	development of written language 136
white matter 13, 27	diffusion tensor imaging (DTI) 13, 71, 106, 339	interventions 137
abnormalities in autism 240	working memory	neuroanatomical features 137
abnormalities following MTX	children with cerebral palsy 208	subtypes of 136–137
chemotherapy 381, 382–384	children treated for brain tumors 401	